SCHEMBL3018952

SCHEMBL3018952

COc1ccc(OC)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
HSD17B10 Q99714 2/20 0.56
USP2 O75604 1/20 0.56
RECQL P46063 1/20 0.56
REV1 Q9UBZ9 1/20 0.54
POLB P06746 2/20 0.48
ALDH1A1 P00352 7/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
ALOX12 P18054 1/20 0.47
KDM1A O60341 3/20 0.47
LMNA P02545 5/20 0.44
MAPK1 P28482 3/20 0.44
HTT P42858 1/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.44
KCNQ1 P51787 1/20 0.44
MAOA P21397 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002608 0.93 MAPT (0.56) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3010055 0.92 MAPT (0.54) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3022585 0.90 MAPT (0.59) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3019570 0.90 KDM1A (0.59) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3005698 0.89 MAPT (0.64) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3005789 0.89 MAPT (0.56) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3014735 0.89 MAPT (0.56) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3003769 0.89 MAPT (0.58) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3003799 0.88 MAPT (0.58) MAPTHSD17B10USP2RECQLREV1
SCHEMBL3016874 0.88 MAPT (0.63) MAPTHSD17B10USP2RECQLREV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.